Literature DB >> 19853478

Changing trends in infectious disease in heart transplantation.

François Haddad1, Tobias Deuse, Michael Pham, Prateeti Khazanie, Fernando Rosso, Helen Luikart, Hannah Valantine, Sebastian Leon, Thu A Vu, Sharon A Hunt, Philip Oyer, Jose G Montoya.   

Abstract

BACKGROUND: During the past 25 years, advances in immunosuppression and the use of selective anti-microbial prophylaxis have progressively reduced the risk of infection after heart transplantation. This study presents a historical perspective of the changing trends of infectious disease after heart transplantation.
METHODS: Infectious complications in 4 representative eras of immunosuppression and anti-microbial prophylaxis were analyzed: (1) 38 in the pre-cyclosporine era (1978-1980), (2) 72 in the early cyclosporine era (1982-1984), where maintenance immunosuppression included high-dose cyclosporine and corticosteroid therapy; (3) 395 in the cyclosporine era (1988-1997), where maintenance immunosuppression included cyclosporine, azathioprine, and lower corticosteroid doses; and (4) 167 in the more recent era (2002-2005), where maintenance immunosuppression included cyclosporine and mycophenolate mofetil.
RESULTS: The overall incidence of infections decreased in the 4 cohorts from 3.35 episodes/patient to 2.03, 1.35, and 0.60 in the more recent cohorts (p < 0.001). Gram-positive bacteria are emerging as the predominant cause of bacterial infections (28.6%, 31.4%, 51.0%, 67.6%, p = 0.001). Cytomegalovirus infections have significantly decreased in incidence and occur later after transplantation (88 +/- 77 days, pre-cyclosporine era; 304 +/- 238 days, recent cohort; p < 0.001). Fungal infections also decreased, from an incidence of 0.29/patient in the pre-cyclosporine era to 0.08 in the most recent era. A major decrease in Pneumocystis jiroveci and Nocardia infections has also occurred.
CONCLUSIONS: The overall incidence and mortality associated with infections continues to decrease in heart transplantation and coincides with advances in immunosuppression, the use of selective anti-microbial prophylaxis, and more effective treatment regimens.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19853478     DOI: 10.1016/j.healun.2009.08.018

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  6 in total

1.  A case of central nervous system nocardiosis in a patient with lupus treated with belimumab.

Authors:  Richard Hc Lai; Deborah Kim; Florina Constantinescu
Journal:  Eur J Rheumatol       Date:  2016-12-01

2.  Outcomes of Pneumocystis jiroveci pneumonia infections in pediatric heart transplant recipients.

Authors:  Benton Ng; Anne Dipchand; David Naftel; Paolo Rusconi; Gerard Boyle; Theo Zaoutis; R Erik Edens
Journal:  Pediatr Transplant       Date:  2011-12

Review 3.  Pentamidine in Pneumocystis jirovecii prophylaxis in heart transplant recipients.

Authors:  Adem Ilkay Diken; Ozlem Erçen Diken; Onur Hanedan; Seyhan Yılmaz; Ata Niyazi Ecevit; Emir Erol; Adnan Yalçınkaya
Journal:  World J Transplant       Date:  2016-03-24

4.  Nocardia infections in the transplanted host.

Authors:  Marion Hemmersbach-Miller; Jason E Stout; Michael H Woodworth; Gary M Cox; Jennifer L Saullo
Journal:  Transpl Infect Dis       Date:  2018-05-07       Impact factor: 2.228

5.  Late presentation of Pneumocystis jiroveci pneumonia after cardiac transplantation.

Authors:  L R Craker
Journal:  BMJ Case Rep       Date:  2010-10-22

6.  Fatal Case of Probable Invasive Aspergillosis after Five Years of Heart Transplant: A Case Report and Review of the Literature.

Authors:  Toufik Mahfood Haddad; Mahesh Anantha Narayanan; Krista E Shaw; Renuga Vivekanandan
Journal:  Case Rep Infect Dis       Date:  2015-08-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.